Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial.
- DOI
- 10.1016/s0140-6736(10)62305-7
- Published
- 2011-03-01
- Container
- Lancet
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/s0140-6736-10-62305-7,
title = {Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial.},
author = {Zinman B and Fulcher G and Rao PV and Thomas N and Endahl LA and Johansen T and Lindh R and Lewin A and Rosenstock J and Pinget M and Mathieu C.},
year = {2011},
journal = {Lancet},
doi = {10.1016/s0140-6736(10)62305-7},
url = {https://doi.org/10.1016/s0140-6736(10)62305-7}
}RIS
TY - JOUR TI - Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. AU - Zinman B AU - Fulcher G AU - Rao PV AU - Thomas N AU - Endahl LA AU - Johansen T AU - Lindh R AU - Lewin A AU - Rosenstock J AU - Pinget M AU - Mathieu C. PY - 2011 JO - Lancet DO - 10.1016/s0140-6736(10)62305-7 UR - https://doi.org/10.1016/s0140-6736(10)62305-7 ER -
APA
B, Z., G, F., PV, R., N, T., LA, E., T, J., R, L., A, L., J, R., M, P., & C., M. (2011). Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial.. Lancet. https://doi.org/10.1016/s0140-6736(10)62305-7
Source records
- europe-pmc · retrieved 2026-09-27T10:30:24.370Z
- hal · retrieved 2026-09-27T10:30:24.405Z